CN106138487A - 一种治疗乳腺纤维腺瘤的中西医结合药物及制备方法 - Google Patents
一种治疗乳腺纤维腺瘤的中西医结合药物及制备方法 Download PDFInfo
- Publication number
- CN106138487A CN106138487A CN201610697047.7A CN201610697047A CN106138487A CN 106138487 A CN106138487 A CN 106138487A CN 201610697047 A CN201610697047 A CN 201610697047A CN 106138487 A CN106138487 A CN 106138487A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese
- radix
- medicine
- western medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 108
- 206010001233 Adenoma benign Diseases 0.000 title claims abstract description 49
- 208000007659 Fibroadenoma Diseases 0.000 title claims abstract description 40
- 201000003149 breast fibroadenoma Diseases 0.000 title claims abstract description 40
- 210000005075 mammary gland Anatomy 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 39
- 241000628997 Flos Species 0.000 claims abstract description 15
- 241000594394 Hedyotis Species 0.000 claims abstract description 15
- 240000009033 Lindernia ruellioides Species 0.000 claims abstract description 15
- 241000006302 Usnea Species 0.000 claims abstract description 15
- 229960000473 altretamine Drugs 0.000 claims abstract description 15
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims abstract description 15
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 claims abstract description 15
- 229960004616 medroxyprogesterone Drugs 0.000 claims abstract description 15
- 239000004615 ingredient Substances 0.000 claims abstract description 14
- 229960004630 chlorambucil Drugs 0.000 claims abstract description 13
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims description 20
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 9
- 210000004072 lung Anatomy 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 244000025254 Cannabis sativa Species 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 235000011837 pasties Nutrition 0.000 claims description 3
- -1 filters Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000003973 paint Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 12
- 238000002651 drug therapy Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 3
- 210000000481 breast Anatomy 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 12
- 208000004396 mastitis Diseases 0.000 description 12
- 231100000614 poison Toxicity 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 10
- 239000003440 toxic substance Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 208000003200 Adenoma Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 239000002435 venom Substances 0.000 description 6
- 231100000611 venom Toxicity 0.000 description 6
- 210000001048 venom Anatomy 0.000 description 6
- 206010017553 Furuncle Diseases 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000008736 traumatic injury Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000000762 glandular Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 201000004471 adenofibroma Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LAOOXBLMIJHMFO-UHFFFAOYSA-N 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one;hydron;chloride Chemical compound Cl.S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC LAOOXBLMIJHMFO-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 206010006223 Breast discharge Diseases 0.000 description 1
- 206010006272 Breast mass Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016322 Feeling abnormal Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010026827 March haemoglobinuria Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000009058 cervical adenitis Diseases 0.000 description 1
- 208000012751 cervical lymphadenitis Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000010582 ecthyma Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000001843 schistosomicidal effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/09—Lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗乳腺纤维腺瘤的中西医结合药物及制备方法,属医药技术领域;本发明中西医结合药物有效成分的原料组成为:六甲蜜胺、苯丁酸氮芥、甲羟孕酮、粗叶悬钩子、橘叶、肺形草、菱、旱田草、耳草、琴叶榕、小叶金老梅、蘡薁、云南仙人掌、鸦葱、松萝和漆大姑根;本发明中西医结合药物治疗乳腺纤维腺瘤比一般单纯用中医和西医治疗效果更佳,可以最大限度地提高中药和西药的功效,且针对性强,疗效显著,安全可靠,标本兼治,费用较低,总有效率高达96.6%。
Description
所属技术领域
本发明涉及医药技术领域,尤其涉及一种治疗乳腺纤维腺瘤的中西医结合药物及制备方法。
背景技术
乳腺纤维腺瘤是由腺上皮和纤维组织两种成分混合组成的良性肿瘤,好发于青年女性,与患者体内性激素水平失衡有关。对本病的认识还有腺纤维瘤、腺瘤之称,是由于构成肿瘤的纤维成分和腺上皮增生程度的不同所致。当肿瘤构成以腺上皮增生为主,而纤维成分较少时称为纤维腺瘤;若纤维组织在肿瘤中占多数,腺管成分较少时,称为腺纤维瘤;肿瘤组织由大量腺管成分组成时,则称为腺瘤。上述三种分类只是病理形态学方面的差异,其临床表现、治疗及预后并无不同,故统称为纤维腺瘤。
乳腺纤维腺瘤主要为乳房无痛性肿块,很少伴有乳房疼痛或乳头溢液。肿块往往是无意中、洗澡时,或体检中被发现。单发肿块居多,亦可多发,也可两侧乳房同时或先后触及肿块。境界清楚,边缘整齐,表面光滑,富有弹性,无压痛,活动度较大,与皮肤无粘连。卵巢功能旺盛,雌激素水平过高,调节失衡,加之患者对雌激素反应敏感,在雌激素的长期刺激下,引起乳腺腺上皮组织和纤维组织过度增生,结构紊乱,形成肿瘤。乳腺纤维腺瘤好发于乳房外上象限,呈圆形或卵圆形,临床多见1~3cm,生长缓慢,妊娠或哺乳期时可急骤增长。极少数青春期发生的纤维腺瘤可在短时间内迅速增大,直径可达8~10cm,称为巨大纤维腺瘤,仍属良性肿瘤。
目前,西医认为引起乳腺纤维腺瘤的病因主要是雌激素对乳腺组织的持续刺激和乳腺组织对雌激素的高反应性,以及与患者服用某些药物或病毒感染、自身基因的突变等。西医普遍采用手术治疗或药物治疗乳腺纤维腺瘤,手术治疗将肿瘤切除,这种方法疗效快,但费用高,承受的开刀痛苦较大,而药物治疗主要是消炎药和抗生素,这些药物治标不治本,服药时间长,且容易复发,给患者带来了极大的心理和经济负担。
发明内容
本发明提供了一种治疗乳腺纤维腺瘤的中西医结合药物及制备方法;本发明中西医结合药物治疗乳腺纤维腺瘤比一般单纯用中医和西医治疗效果更佳,可以最大限度地提高中药和西药的功效,且针对性强,疗效显著,安全可靠,标本兼治,费用较低,总有效率高达96.6%。
为实现上述目的,本发明的技术方案实施如下:
一种治疗乳腺纤维腺瘤的中西医结合药物,制成所述中西医结合药物有效成分的原料组成及重量份数为:
六甲蜜胺0.02~0.1份,苯丁酸氮芥0.01~0.06份,甲羟孕酮0.1~0.4份,粗叶悬钩子15~31份,橘叶14~30份,肺形草14~30份,菱13~29份,旱田草12~28份,耳草11~27份,琴叶榕11~27份,小叶金老梅11~27份,蘡薁10~26份,云南仙人掌10~26份,鸦葱9~25份,松萝8~24份和漆大姑根8~24份。
制成所述中西医结合药物有效成分的原料组成及重量份数为:
六甲蜜胺0.04~0.08份,苯丁酸氮芥0.02~0.04份,甲羟孕酮0.12~0.38份,粗叶悬钩子19~27份,橘叶18~26份,肺形草18~26份,菱17~25份,旱田草16~24份,耳草15~23份,琴叶榕15~23份,小叶金老梅15~23份,蘡薁14~22份,云南仙人掌14~22份,鸦葱13~21份,松萝12~20份和漆大姑根12~20份。
制成所述中西医结合药物有效成分的原料组成及重量份数为:
六甲蜜胺0.06份,苯丁酸氮芥0.03份,甲羟孕酮0.25份,粗叶悬钩子23份,橘叶22份,肺形草22份,菱21份,旱田草20份,耳草19份,琴叶榕19份,小叶金老梅19份,蘡薁18份,云南仙人掌18份,鸦葱17份,松萝16份和漆大姑根16份。
一种治疗乳腺纤维腺瘤的中西医结合药物的制备方法,将西药六甲蜜胺、苯丁酸氮芥和甲羟孕酮按比例混合放入药罐内,用搅拌机搅拌均匀,放入烘箱70℃烘干后冷却,提取研末,得到过160目的细粉,备用。
一种治疗乳腺纤维腺瘤的中西医结合药物的制备方法,包括以下中药成分的提取工艺步骤:
(1)将中药粗叶悬钩子、肺形草、菱、旱田草、耳草、琴叶榕、小叶金老梅、鸦葱、松萝和漆大姑根按比例混合放入容器内,加入5~8倍量的蒸馏水,加热煮沸2~3小时,提取,过滤,得滤液,加热浓缩至糊状,放入烘箱70℃烘干后冷却,提取研末,得到过180目的细粉,备用;
(2)将中药橘叶、蘡薁和云南仙人掌洗净,切碎,放入容器内,绞汁,滤杂质,留汁液备用;
(3)将上述步骤(1)、步骤(2)获得的细粉、汁液进行混合,搅拌溶解均匀后,加热浓缩成稠膏,备用。
一种治疗乳腺纤维腺瘤的中西医结合药物的制备方法,将所述西药细粉和中药稠膏进行混合,搅拌溶解均匀后,提取制成片剂,即得所述的治疗乳腺纤维腺瘤的中西医结合药物。
本发明所用中西药的药性如下:
六甲蜜胺:本品为白色结晶性粉末,无臭,在氯仿中易溶,在乙醇中略溶,在水中不溶,在稀盐酸中易溶。主要治疗卵巢癌,也可用于治疗支气管肺癌、乳腺癌和恶性淋巴瘤等。
苯丁酸氮芥:主要用于慢性淋巴细胞白血病,也适用于恶性淋巴瘤、多发性骨髓瘤、巨球蛋白血症、卵巢癌。
甲羟孕酮:为白色或类白色结晶性粉末,无臭,不溶于水,易溶于氯仿,微溶于无水乙醇。主要用于治疗肾癌、乳腺癌、子宫内膜癌、前列腺癌及增强晚期癌症病人的食欲,改善一般状况和增加体重。
粗叶悬钩子:味甘、淡,性平;归胃、肝经。清热利湿,止血,散瘀。主肝炎,痢疾,肠炎,乳腺炎,口腔炎,行军性血红蛋白尿,外伤出血,肝脾肿大,跌打损伤,风湿骨痛。广州部队《常用中草药手册》载:“活血祛瘀,清热止血。”
橘叶:味苦、辛,性平;归肝经。疏肝行气,化痰散结。主乳痈,乳房结块,胸胁胀痛,疝气。
肺形草:味辛、甘、苦;归肺、肾经。清肺止咳,凉血止血,利尿解毒。主肺热咳嗽,肺痨咯血,肺痈,肾炎,乳痈,疮痈疔肿,创伤出血,毒蛇咬伤。
菱:味甘,性凉;归脾、胃经。健脾益胃,除烦目渴,解毒。主脾虚泄泻,暑热烦渴,饮酒过度,痢疾。
旱田草:味甘、淡,性平。理气活血,解毒消肿。主月经不调,痛经,闭经,胃痛,乳痈,瘰疬,跌打损伤,蛇犬咬伤。
耳草:味苦,性凉。清热解毒,凉血消肿。主感冒发热,肺热咳嗽,咽喉肿痛,肠炎,痢疾,痔疮出血,崩漏,毒蛇咬伤,乳腺炎,痈疖肿毒,湿疹,跌打损伤。
琴叶榕:味甘、微辛,性平。祛风除湿,解毒消肿,活血通经。主风湿痹痛,黄疽,疟疾,百日咳,乳汁不通,乳痈,痛经,闭经,痈疖肿痛,跌打损伤,毒蛇咬伤。
小叶金老梅:味甘,性寒;归肾、膀胱二经。利尿消水。治寒湿脚气,痒疹,乳腺炎。
蘡薁:味甘、酸,性平;归肝、胃经。祛湿,利小便,解毒。治淋病,痢疾,痹痛,扃症,哕逆,瘰疬,乳痈,湿疹,臁疮。
云南仙人掌:味苦,性凉。清热解毒,消肿散结。主治腮腺炎,乳腺炎,疖疮痈肿,毒蛇咬伤。
鸦葱:味微苦、涩,性寒;归心经。消肿解毒。主五痨七伤,疔疮痈肿。
松萝:味甘、苦,性平;归心、肾、肺经。祛痰止咳,清热解毒,除湿通络,止血调经,驱虫。主痰热温疟,咳喘,肺痨,头痛,目赤云翳,痈肿疮毒,瘰疠,乳痈,烫火伤,毒蛇咬伤,风温痹痛,跌打损伤,骨折,外伤出血,吐血,便血,崩漏,月经不调,白带,蛔虫病,血吸虫病。《西藏常用中草药》载:“清热解毒,止咳化痰。治外伤感染,化脓性感染,毒蛇咬伤,肺结核咳嗽痰多,颈淋巴腺炎,乳腺炎。”
漆大姑根:味苦、涩,性平;归大肠经。清热解毒,祛湿止痒。主肠炎,痢疾,牙痛,咽喉痛,乳腺炎,皮肤湿疹,烧伤,白带。
本发明与现有技术相比,具有以下有益效果:
本发明中西医结合药物治疗乳腺纤维腺瘤比一般单纯用中医和西医治疗效果更佳,可以最大限度地提高中药和西药的功效,且针对性强,疗效显著,安全可靠,标本兼治,费用较低,总有效率高达96.6%。
具体实施方式
下面结合具体实施例对本发明做进一步阐述。
实施例1
本发明中西医结合药物有效成分的原料组成及重量为:
六甲蜜胺0.08g,苯丁酸氮芥0.04g,甲羟孕酮0.38g,粗叶悬钩子27g,橘叶26g,肺形草26g,菱25g,旱田草24g,耳草23g,琴叶榕23g,小叶金老梅23g,蘡薁22g,云南仙人掌22g,鸦葱21g,松萝20g和漆大姑根20g。
一种治疗乳腺纤维腺瘤的中西医结合药物的制备方法,将西药六甲蜜胺、苯丁酸氮芥和甲羟孕酮按比例混合放入药罐内,用搅拌机搅拌均匀,放入烘箱70℃烘干后冷却,提取研末,得到过160目的细粉,备用。
一种治疗乳腺纤维腺瘤的中西医结合药物的制备方法,包括以下中药成分的提取工艺步骤:
(1)将中药粗叶悬钩子、肺形草、菱、旱田草、耳草、琴叶榕、小叶金老梅、鸦葱、松萝和漆大姑根按比例混合放入容器内,加入5~8倍量的蒸馏水,加热煮沸2~3小时,提取,过滤,得滤液,加热浓缩至糊状,放入烘箱70℃烘干后冷却,提取研末,得到过180目的细粉,备用;
(2)将中药橘叶、蘡薁和云南仙人掌洗净,切碎,放入容器内,绞汁,滤杂质,留汁液备用;
(3)将上述步骤(1)、步骤(2)获得的细粉、汁液进行混合,搅拌溶解均匀后,加热浓缩成稠膏,备用。
一种治疗乳腺纤维腺瘤的中西医结合药物的制备方法,将所述西药细粉和中药稠膏进行混合,搅拌溶解均匀后,提取制成片剂,即得所述的治疗乳腺纤维腺瘤的中西医结合药物。
用法用量:口服,每日2次,早晚各1次,每次2片,温开水送服;7天为1个疗程,3~6个疗程即可痊愈,病情严重者遵医嘱酌增用量。
实施例2
本发明中西医结合药物有效成分的原料组成及重量为:
六甲蜜胺0.06g,苯丁酸氮芥0.03g,甲羟孕酮0.25g,粗叶悬钩子23g,橘叶22g,肺形草22g,菱21g,旱田草20g,耳草19g,琴叶榕19g,小叶金老梅19g,蘡薁18g,云南仙人掌18g,鸦葱17g,松萝16g和漆大姑根16g。
本实施例的中西医结合药物制备方法工艺步骤及用法用量与实施例1相同。实施例3
本发明中西医结合药物有效成分的原料组成及重量为:
六甲蜜胺0.04g,苯丁酸氮芥0.02g,甲羟孕酮0.12g,粗叶悬钩子19g,橘叶18g,肺形草18g,菱17g,旱田草16g,耳草15g,琴叶榕15g,小叶金老梅15g,蘡薁14g,云南仙人掌14g,鸦葱13g,松萝12g和漆大姑根12g。
本实施例的中西医结合药物制备方法工艺步骤及用法用量与实施例1相同。实施例4
本发明中西医结合药物有效成分的原料组成及重量为:
六甲蜜胺0.02g,苯丁酸氮芥0.01g,甲羟孕酮0.1g,粗叶悬钩子15g,橘叶14g,肺形草14g,菱13g,旱田草12g,耳草11g,琴叶榕11g,小叶金老梅11g,蘡薁10g,云南仙人掌10g,鸦葱9g,松萝8g和漆大姑根8g。
本实施例的中西医结合药物制备方法工艺步骤及用法用量与实施例1相同。临床资料:
一、病例选择:
作为治疗乳腺纤维腺瘤的中西医结合药物,选择确诊的乳腺纤维腺瘤患者264例临床观察,病人随机分成治疗组、对照组A和对照组B三组,治疗组女性88例,年龄20~55岁,平均年龄37.5岁,平均病程半年;对照组A女性87例,年龄21~52岁,平均年龄36.5岁,平均病程半年;对照组B女性89例,年龄23~56岁,平均年龄39.5岁,平均病程半年。
治疗组、对照组A和对照组B三组病例的病程、症状轻重程度基本一致,无显著差异,具有可比性。
二、药物选择:
治疗组使用本发明中西医结合药物,口服,每日2次,早晚各1次,每次2片,温开水送服;7天为1个疗程,3~6个疗程即可痊愈,病情严重者遵医嘱酌增用量。
对照组A服用乳癖消片,口服,一次3片,一日3次。
对照组B服用枸橼酸他莫昔芬片,口服,每次10mg(1片),每天2次,也可每次20mg(2片),每天2次。
三、疗效判断:
治愈:乳房肿块以及疼痛症状全部消失,身体恢复健康。显效:乳房肿块明显缩小,疼痛症状明显减轻,身体明显好转。有效:乳房肿块有所缩小,疼痛症状有所减轻,身体明显好转。无效:通过治疗后乳房肿块未见缩小反而增大变硬。
四、治疗结果:
以上结果显示,治疗组的治愈率和总有效率明显高于对照组A和对照组B。
五、典型病例:
1、康某,女,21岁。患者左侧乳房患乳腺纤维腺瘤,在当地医院采用手术摘除治疗,近半年自我检查总感觉手术部位还有硬块感,遂去医院检查,经查体再次确诊为乳腺纤维腺瘤,患者不愿再次手术,后来我院治疗,经服用本发明中西医结合药物治疗,服用2个疗程后,不适症状明显减轻,继续服用4个疗程后,复查肿块消失,无任何不适症状,痊愈,半年后随访无复发。
2、毛某,女,30岁。患者自述偶然发现乳房右侧有两处肿块,去医院检查,两肿块质地中等、边界清楚,推之可移,诊断为乳腺纤维腺瘤,医生给予本发明中西医结合药物治疗,服用1个疗程后,肿块有所缩小,服用3个疗程后,肿块明显缩小,继续服用2个疗程后,经X线检查肿块消失,痊愈,1年后复查无复发。
3、邱某,女,28岁。患者自述在沐浴时意外发现右侧乳房外上象限内有一囊性肿块,情绪不好时出现疼痛感,去医院检查,经X线辅助检查,确诊为乳腺纤维腺瘤,医生给予本发明中西医结合药物治疗,服用2个疗程后,疼痛症状明显好转,肿块明显缩小,继续服用3个疗程后,疼痛症状消失,经X线检查腺瘤消失,痊愈。
4、秦某,女,35岁。患者自述平日工作压力大,经常熬夜加班,月经不规律,在洗澡时意外发现左侧乳房有一肿块,去医院检查,诊断为乳腺纤维腺瘤,使用过药物治疗,治疗效果不明显,后来我院治疗,经服用本发明中西医结合药物治疗,服用2个疗程后,肿块明显缩小,服用5个疗程后,肿块消失,痊愈,半年后复查无复发。
5、江某,女,46岁。患者在单位门诊体检时,发现右侧乳房无痛性肿块,经X线检查后确诊为乳腺纤维腺瘤,使用过药物治疗,治疗效果一般,后来我院治疗,经服用本发明中西医结合药物治疗,服用1个疗程后,肿块有所缩小,服用2个疗程后,肿块明显缩小,继续服用3个疗程后,肿块消失,痊愈,1年后复查无复发。
6、顾某,女,51岁。患者自述因工作压力大,性格急躁。3年前查出有乳腺增生,一直服用药物治疗,症状时好时坏,复诊时又在同区域发现乳腺纤维腺瘤,虽然活动度好,但情绪激动时会出现明显刺痛感,经医生给予本发明中西医结合药物治疗,服用1个疗程后,症状有所缓解,服用2个疗程后,症状明显缓解,腺瘤缩小,继续服用2个疗程后,症状消失,经X线检查腺瘤也消失,痊愈,1年后复查无复发。
最后应说明的是:以上所述,仅是本发明的较佳实施例而已,并非是对本发明作其它形式的限制,凡是未脱离本发明技术方案内容,依据本发明的申请范围内所做的任何修改、等同替换和改进等,仍属于本发明技术方案的保护范围。
Claims (6)
1.一种治疗乳腺纤维腺瘤的中西医结合药物,其特征在于:制成所述中西医结合药物有效成分的原料组成及重量份数为:
六甲蜜胺0.02~0.1份,苯丁酸氮芥0.01~0.06份,甲羟孕酮0.1~0.4份,粗叶悬钩子15~31份,橘叶14~30份,肺形草14~30份,菱13~29份,旱田草12~28份,耳草11~27份,琴叶榕11~27份,小叶金老梅11~27份,蘡薁10~26份,云南仙人掌10~26份,鸦葱9~25份,松萝8~24份和漆大姑根8~24份。
2.根据权利要求1所述的一种治疗乳腺纤维腺瘤的中西医结合药物,其特征在于:制成所述中西医结合药物有效成分的原料组成及重量份数为:
六甲蜜胺0.04~0.08份,苯丁酸氮芥0.02~0.04份,甲羟孕酮0.12~0.38份,粗叶悬钩子19~27份,橘叶18~26份,肺形草18~26份,菱17~25份,旱田草16~24份,耳草15~23份,琴叶榕15~23份,小叶金老梅15~23份,蘡薁14~22份,云南仙人掌14~22份,鸦葱13~21份,松萝12~20份和漆大姑根12~20份。
3.根据权利要求1所述的一种治疗乳腺纤维腺瘤的中西医结合药物,其特征在于:制成所述中西医结合药物有效成分的原料组成及重量份数为:
六甲蜜胺0.06份,苯丁酸氮芥0.03份,甲羟孕酮0.25份,粗叶悬钩子23份,橘叶22份,肺形草22份,菱21份,旱田草20份,耳草19份,琴叶榕19份,小叶金老梅19份,蘡薁18份,云南仙人掌18份,鸦葱17份,松萝16份和漆大姑根16份。
4.一种如权利要求1~3任一项所述治疗乳腺纤维腺瘤的中西医结合药物的制备方法,其特征在于:将西药六甲蜜胺、苯丁酸氮芥和甲羟孕酮按比例混合放入药罐内,用搅拌机搅拌均匀,放入烘箱70℃烘干后冷却,提取研末,得到过160目的细粉,备用。
5.一种如权利要求1~3任一项所述治疗乳腺纤维腺瘤的中西医结合药物的制备方法,其特征在于:包括以下中药成分的提取工艺步骤:
(1)将中药粗叶悬钩子、肺形草、菱、旱田草、耳草、琴叶榕、小叶金老梅、鸦葱、松萝和漆大姑根按比例混合放入容器内,加入5~8倍量的蒸馏水,加热煮沸2~3小时,提取,过滤,得滤液,加热浓缩至糊状,放入烘箱70℃烘干后冷却,提取研末,得到过180目的细粉,备用;
(2)将中药橘叶、蘡薁和云南仙人掌洗净,切碎,放入容器内,绞汁,滤杂质,留汁液备用;
(3)将上述步骤(1)、步骤(2)获得的细粉、汁液进行混合,搅拌溶解均匀后,加热浓缩成稠膏,备用。
6.根据权利要求4或权利要求5所述治疗乳腺纤维腺瘤的中西医结合药物的制备方法,其特征在于:将所述西药细粉和中药稠膏进行混合,搅拌溶解均匀后,提取制成片剂,即得所述的治疗乳腺纤维腺瘤的中西医结合药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610697047.7A CN106138487A (zh) | 2016-08-22 | 2016-08-22 | 一种治疗乳腺纤维腺瘤的中西医结合药物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610697047.7A CN106138487A (zh) | 2016-08-22 | 2016-08-22 | 一种治疗乳腺纤维腺瘤的中西医结合药物及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106138487A true CN106138487A (zh) | 2016-11-23 |
Family
ID=57342092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610697047.7A Pending CN106138487A (zh) | 2016-08-22 | 2016-08-22 | 一种治疗乳腺纤维腺瘤的中西医结合药物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106138487A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1435229A (zh) * | 2002-12-12 | 2003-08-13 | 中国人民解放军第四军医大学药物研究所 | 二贝母胶囊及其制备工艺 |
CN1891288A (zh) * | 2005-07-08 | 2007-01-10 | 吴逸芳 | 一种中药组合物及其制备方法和质量控制方法 |
-
2016
- 2016-08-22 CN CN201610697047.7A patent/CN106138487A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1435229A (zh) * | 2002-12-12 | 2003-08-13 | 中国人民解放军第四军医大学药物研究所 | 二贝母胶囊及其制备工艺 |
CN1891288A (zh) * | 2005-07-08 | 2007-01-10 | 吴逸芳 | 一种中药组合物及其制备方法和质量控制方法 |
Non-Patent Citations (1)
Title |
---|
王秀芳,郑瑶主编: "《临床常见病的中药治疗》", 31 July 2008 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103816504A (zh) | 一种活血止痛膏及其制备方法 | |
CN104491737A (zh) | 一种治疗早期肝癌的中药配方 | |
CN104013919A (zh) | 一种治疗心绞痛的中药 | |
CN104324317B (zh) | 一种治疗子宫肌瘤的中药组合物及医药用途 | |
CN103393943B (zh) | 一种治疗脑梗塞后遗症的中药组合物 | |
CN102846770A (zh) | 一种治疗便秘的纯中药胶囊 | |
CN103285203B (zh) | 用于预防和治疗骨折的中药组合物及其制备方法 | |
CN104645232A (zh) | 一种治疗双曲综合征的中药复合组合物及其制备方法和应用 | |
CN105770691A (zh) | 一种用于治疗宫颈癌的药物制剂及其用途 | |
CN103735851B (zh) | 一种治疗骨折的中药制剂 | |
CN102302736A (zh) | 一种治疗脂肪瘤病的中药 | |
CN106138487A (zh) | 一种治疗乳腺纤维腺瘤的中西医结合药物及制备方法 | |
CN104873602A (zh) | 一种治疗乳腺增生的中药 | |
CN104338052A (zh) | 治疗脑血栓的中药配方 | |
CN103721028B (zh) | 一种治疗心绞痛的药物及制备方法 | |
CN102895564A (zh) | 一种治疗输卵管不通的中药及其制备方法 | |
CN101732648B (zh) | 一种治疗骨不连的药物 | |
CN106177785A (zh) | 一种治疗颈椎病的药物 | |
CN105998968A (zh) | 一种治疗湿热型外阴炎的药物组合物 | |
CN105168945A (zh) | 一种用于促进骨折愈合的外用药膏及制备方法 | |
CN104352843A (zh) | 骨伤愈后舒筋通络制剂及制备方法 | |
CN104510835A (zh) | 一种治疗肠道肿瘤的中药配方 | |
CN103816496B (zh) | 一种治疗心律失常的中药 | |
CN104666922A (zh) | 一种治疗脾肾气虚型月经不调的中药组合物 | |
CN104352573B (zh) | 一种治疗阳水肿的中药丸 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161123 |
|
RJ01 | Rejection of invention patent application after publication |